佐福替尼(Ziftomenib) - 药物靶点：MLL1 x menin_在研适应症：NPM1突变急性髓系白血病，急性髓性白血病，伴有 11q23 异常的急性髓系白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

齐夫托美尼布、KO-381、KO-382

+ [4]

靶点

MLL1 x menin

作用方式

抑制剂

作用机制

MLL1抑制剂(lysine methyltransferase 2A inhibitors)、menin抑制剂(Menin蛋白抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病免疫系统疾病+ [3]

在研适应症

NPM1突变急性髓系白血病急性髓性白血病伴有 11q23 异常的急性髓系白血病+ [9]

非在研适应症-

原研机构

Kura Oncology, Inc.

在研机构

Kura Oncology, Inc.

Kura Ltd.Sti.

Kyowa Kirin Co., Ltd.

非在研机构-

权益机构

Kyowa Kirin Co., Ltd.

The University of Texas MD Anderson Cancer Center

Kura Oncology, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2025-11-13),

NPM1突变急性髓系白血病

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、优先审评 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C33H42F3N9O2S2

InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N

CAS号2134675-36-6

关联

16

项与佐福替尼相关的临床试验

NCT06930352

/ Recruiting临床2期IIT

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

开始日期2026-10-01

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

NCT07355335

/ Not yet recruiting临床1期IIT

A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

开始日期2026-07-09

申办/合作机构

The Massachusetts General Hospital

[+2]

NCT07411586

/ Active, not recruiting临床1期IIT

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes.
The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 can help to control the disease.
The safety and effects of this combination will also be studied in both parts.

开始日期2026-05-28

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与佐福替尼相关的临床结果

登录后查看更多信息

100 项与佐福替尼相关的转化医学

登录后查看更多信息

100 项与佐福替尼相关的专利（医药）

登录后查看更多信息

54

项与佐福替尼相关的文献（医药）

2026-11-01·MEDICINAL RESEARCH REVIEWS

Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025

Review

作者: Li, Zhen ; Wang, Min ; Zhang, Huijie ; Chang, Liang ; Song, Zixuan ; Wang, Jiao ; Jiang, Fengli ; Zhao, Lijie ; Quan, Yuan

ABSTRACT:

In 2025, the U.S. Food and Drug Administration (FDA) continued to advance therapeutic innovation by approving a diverse range of novel drugs. According to the FDA's 2025 Novel Drug Approvals list, 46 new drugs received approval, including both new chemical entities such as Ziftomenib, Sevabertinib, Zoliflodacin, and Gepotidacin, as well as new biologics. These approvals cover a wide range of therapeutic areas, including oncology, rare genetic diseases, infectious diseases, cardiovascular diseases, and immunomodulation. A significant proportion of the approved products navigated accelerated or priority review pathways, reflecting their potential impact on unmet medical needs. This review provides a comprehensive overview of the synthetic routes and clinical applications of FDA‐approved small‐molecule drugs in 2025, aiming to inspire future development in drug discovery.

2026-10-01·Clinical Lymphoma Myeloma & Leukemia

Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success

Review

作者: Vatteroni, Alessandra ; Simio, Claudia

Menin inhibitors (MIs) represent a novel class of targeted agents that disrupt the interaction between the nuclear protein menin and the KMT2A (MLL) complex, thereby interrupting a crucial oncogenic transcriptional program in acute myeloid leukemias (AML) with KMT2A rearrangements and NPM1 mutations. Robust preclinical data have shown that menin inhibition suppresses HOXA/MEIS1 expression, induces differentiation, and reduces the fitness of leukemic cells, including the stem-like compartment. These findings rapidly led to phase I/II clinical trials with oral MIs such as revumenib and ziftomenib, which demonstrated CR+CRh rates of 22% to 23% in refractory/relapsed patients, with conversion to measurable residual disease (MRD) negativity in 61% to 68% of responders and early use as a bridge to allogeneic transplantation. However, the median duration of response remains limited (approximately 4-5 months), suggesting that menin inhibition as monotherapy may be insufficient to ensure durable disease control. Key emerging clinical issues include specific adverse events (QTc prolongation in 12%-44%, differentiation syndrome in 10%-29%), drug-drug interactions mediated by CYP3A4 metabolism, resistance dynamics (on-target mutations in 39% of cases), and the definition of the optimal role in combination with venetoclax, hypomethylating agents, and intensive chemotherapy. This review synthesizes molecular mechanisms, preclinical and clinical data, discusses use within MRD-guided and transplant pathways, and proposes translational priorities for integrating MIs into future therapeutic paradigms, pending confirmation from randomized studies.

2026-10-01·BLOOD

Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1 -mutated acute myeloid leukemia

Article

作者: Badar, Talha ; Qasrawi, Ayman H. ; Juckett, Mark B. ; Mangan, James K. ; Osman, Diaa ; Yaghmour, George ; McCloskey, James ; Soifer, Harris S. ; Schiller, Gary J. ; Advani, Anjali S. ; Balasubramanian, Suresh Kumar ; Altman, Jessica K. ; Wang, Eunice S. ; Tian, Ying ; Lin, Tara L. ; Zeidan, Amer M. ; Gojo, Ivana ; Erba, Harry ; Guru Murthy, Guru Subramanian ; Khawandanah, Mohamad ; Zhang, Hongling ; Madanat, Yazan F. ; Fathi, Amir T. ; Riches, Marcie ; Leoni, Mollie ; Alsfeld, Leonard C. ; Rotta, Marcello ; Issa, Ghayas C. ; McMahon, Christine M. ; Naqvi, Kiran ; Corum, Daniel ; Palmisiano, Neil D. ; Strickland, Stephen A. ; Roboz, Gail J. ; Saliba, Antoine N. ; Pratz, Keith W.

Abstract:

Ziftomenib, a potent, selective, oral menin inhibitor, is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard therapies for R/R and newly diagnosed AML. Here, we report the outcomes of adults with R/R NPM1-m AML treated with ziftomenib plus venetoclax/azacitidine. In phase 1a, patients received ziftomenib 200, 400, or 600 mg once daily with standard doses of venetoclax/azacitidine. In phase 1b, ziftomenib 600 mg was selected for expansion. A total of 67 patients were treated (27 phase 1a; 40 phase 1b). Median age was 66 years; 55% were male. Median number of previous therapies was 1 (range, 1-8); 55% received previous venetoclax, and 22% had received previous transplantation. Most common (≥20%) grade ≥3 treatment-emergent adverse events were leukopenia (34%), thrombocytopenia (28%), febrile neutropenia and neutropenia (25% each). Six patients developed corrected QT prolongation (1 ziftomenib-related; grade 1), and 2 experienced differentiation syndrome (grade 3); all events were successfully managed. In patients receiving ziftomenib 600 mg, composite complete remission (CRc) rate was 46% (22/48), with 67% (12/18) achieving central measurable residual disease (MRD) negativity (<0.01% threshold). In venetoclax-naïve and -exposed patients, CRc rates were 70% (16/23) and 24% (6/25), with MRD negativity rates of 75% (9/12) and 50% (3/6), respectively. Median duration of response was 8.6 months, and median overall survival was not reached. The combination of ziftomenib 600 mg with venetoclax/azacitidine was well tolerated with deep and durable clinical activity in R/R NPM1-m AML. This trial was registered at www.clinicaltrials.gov as NCT05735184.

361

项与佐福替尼相关的新闻（医药）

2026-10-07

·BioSpace

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62 nd European Association for the Study of Diabetes (EASD) Annual Meeting. Virtual Investor Event Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay will be available on under the Investors tab in the Events and Presentations section. About Caspian Therapeutics Caspian Therapeutics is pioneering menin-directed therapies in diabetes and other cardiometabolic diseases. Built on more than a decade of menin-inhibitor research at Kura Oncology, Caspian combines deep expertise in menin biology and medicinal chemistry with a development strategy focused on the requirements of diabetes and other cardiometabolic diseases. Caspian’s lead compound, KO-7246, is a next-generation, highly selective and orally bioavailable menin inhibitor intended for metabolic applications and is currently in IND-enabling development. Caspian plans to evaluate KO-7246 in a Phase 1 program designed to assess its potential to restore functional β-cell capacity and endogenous insulin production in patients with diabetes. Caspian also plans to advance a second development candidate for additional cardiometabolic indications. To learn more, visit . About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small-molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI ® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn . Contacts Caspian Therapeutics Robert Spencer, Ph.D. rob@caspiantx.com Kura Oncology Greg Mann 858-987-4046 gmann@kuraoncology.com

上市批准临床1期

2026-10-04

·BioSpace

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $10.65 per share, the closing price of the Company’s common stock on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI ® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn . Kura Contact Investors and Media: Greg Mann 858-987-4046 gmann@kuraoncology.com

上市批准

2026-10-02

·GlobeNewswire-Health Care

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $10.65 per share, the closing price of the Company’s common stock on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn. Kura Contact Investors and Media:Greg Mann858-987-4046gmann@kuraoncology.com

上市批准

100 项与佐福替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12419	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
NPM1突变急性髓系白血病	美国	Kura Oncology, Inc.	2025-11-13
NPM1突变急性髓系白血病	美国	Kura Ltd.Sti.	2025-11-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床3期	澳大利亚	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	比利时	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	加拿大	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	捷克	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	法国	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	德国	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	希腊	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	匈牙利	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	意大利	Kura Oncology, Inc.	2025-09-26
急性髓性白血病	临床3期	菲律宾	Kura Oncology, Inc.	2025-09-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07007312 (KOMET-017, EHA2026)	临床3期	伴有 11q23 异常的急性髓系白血病 \| NPM1突变急性髓系白血病一线 NPM1 mutations \| KMT2A rearrangements	351	ziftomenib during 7+3 induction and cytarabine consolidation, and placebo during maintenance	壓製顧膚願餘顧獵鹹齋(廠齋淵衊鹹繭壓鹽鹽糧) = 糧鹽廠鹽齋餘廠鑰衊淵構蓋積鑰鹽窪壓遞夢廠 (醖憲壓積製醖膚糧襯糧 ) 更多	积极	2026-05-12
NCT05735184 (KOMET-007, ASH2025)	临床1期	NPM1突变急性髓系白血病 NPM1-mutation	39	AzacitidineVenetoclax 600 mg + AzacitidineVenetoclax + AzacitidineVenetoclaxe (Newly diagnosed NPM1-m AML)	鏇鏇憲觸襯選憲遞壓製(築構構獵艱遞鬱築鹹壓) = 簾齋遞鏇鏇憲膚鑰餘艱製窪糧糧衊艱襯襯衊選 (襯鹹鹹壓製餘願鹹壓選 ) 更多	积极	2025-12-06
NCT04067336 (KOMET-001, Pubmed \| J Clin Oncol)	临床1/2期	NPM1突变急性髓系白血病 NPM1-mutated	92	Ziftomenib 600 mg	衊蓋廠簾鏇觸齋獵製衊(範簾蓋鬱願壓膚蓋衊築) = 糧糧窪繭糧壓構築範窪鹹繭獵鹽範遞製淵鑰鏇 (齋鏇築鑰窪獵膚衊衊膚, 14 ~ 32) 更多	积极	2025-11-01
NCT04067336 (KOMET-001, ASCO2025) 人工标引	临床1/2期	NPM1突变急性髓系白血病 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 1b/2)	壓廠鹽獵醖壓簾鏇鹹蓋(構簾積積鏇遞積製範淵) = 餘窪鑰鏇積齋膚製鑰觸觸鹹鬱憲遞繭遞艱選鏇 (製夢壓憲鹽積窪鑰淵範, 17 ~ 34) 更多	积极	2025-05-30
NCT04067336 (KOMET-001, ASCO2025) 人工标引	临床1/2期	NPM1突变急性髓系白血病 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 2)	壓廠鹽獵醖壓簾鏇鹹蓋(構簾積積鏇遞積製範淵) = 鏇襯積艱夢簾憲餘顧願觸鹹鬱憲遞繭遞艱選鏇 (製夢壓憲鹽積窪鑰淵範, 15 ~ 33)	积极	2025-05-30
NCT04067336 (KOMET-001, EHA2025)	临床1/2期	NPM1突变急性髓系白血病 NPM1-mutant	112	Ziftomenib 600 mg QD	齋選顧繭淵齋顧選膚窪(鏇餘齋膚廠淵鑰顧鹽膚) = 窪遞鬱襯獵鑰鬱觸夢淵鏇淵鹽廠構衊繭醖構遞 (襯鑰艱遞鹽繭鏇憲製蓋, 17 ~ 34) 更多	积极	2025-05-22
NCT05735184 (KOMET-007, EHA2025)	临床1期	伴有 11q23 异常的急性髓系白血病 \| NPM1突变急性髓系白血病 NPM1-m \| KMT2A-r	51	Ziftomenib 600 mg QD + 7+3 induction	壓鹽醖餘窪鏇築鏇選廠(選襯鬱範築膚醖簾鏇繭) = febrile neutropenia (47%), decreased platelet count (31%), anemia (22%), decreased neutrophil count (20%), decreased white blood cell count (16%) 鏇鬱憲鑰襯襯製蓋廠憲 (繭鑰糧膚襯鏇衊製遞繭 ) 更多	积极	2025-05-14
NCT04067336 (KOMET-001, Company_Website) 人工标引	临床1/2期	急性髓性白血病 NPM1 Mutation	-	Ziftomenib	醖夢膚積鏇製衊艱觸淵(繭簾鹹廠淵壓鏇構蓋夢) = The KOMET-001 trial achieved its primary endpoint of CR plus CR with partial hematological recovery (CRh) and the primary endpoint was statistically significant. 簾糧蓋鏇壓餘蓋鏇築壓 (製糧廠憲窪淵餘觸遞網 ) 达到更多	积极	2025-02-07
KOMET-007 (GlobeNewswire) 人工标引	临床1期	NPM1突变急性髓系白血病 \| KMT2A易位的急性白血病一线 NPM1 Mutation \| KMT2A Rearrangement	54	ziftomenib +venetoclax/azacitidine	淵夢衊鹹鏇積繭選壓鹹(獵積醖鏇淵鑰糧糧淵鹽) = 鏇築糧夢範簾鑰製夢遞製壓蓋繭衊範蓋廠艱網 (鏇積簾艱糧壓淵觸積構 ) 更多	积极	2024-12-09
KOMET-007 (GlobeNewswire) 人工标引	临床1期		54	Ziftomenib+cytarabinecytarabine/daunorubicindaunorubicin	淵夢衊鹹鏇積繭選壓鹹(獵積醖鏇淵鑰糧糧淵鹽) = 鑰艱鑰齋窪築遞窪淵鬱製壓蓋繭衊範蓋廠艱網 (鏇積簾艱糧壓淵觸積構 ) 更多	积极	2024-12-09
ASH2024	N/A	-	-	Ziftomenib 200 mg	獵鏇願顧壓憲襯醖選醖(願膚繭範鑰製網蓋觸膚) = 繭齋構製範醖網簾積顧網衊簾積鑰餘膚獵觸獵 (製醖築構鹹壓構積襯夢 ) 更多	-	2024-12-08
ASH2024	N/A	-	-	Ziftomenib 400 mg	獵鏇願顧壓憲襯醖選醖(願膚繭範鑰製網蓋觸膚) = 襯廠襯構鑰淵鏇鏇壓範網衊簾積鑰餘膚獵觸獵 (製醖築構鹹壓構積襯夢 ) 更多	-	2024-12-08
ASH2024	N/A	-	-	Ziftomenib 200 mg	鹽齋窪糧膚遞觸範構淵(網窪願築壓鑰顧淵積獵) = 齋繭製觸鹽範醖選觸淵衊顧窪遞獵製鑰餘鏇鹽 (顧襯範淵襯顧襯願鬱壓 )	-	2024-12-07
ASH2024	N/A	-	-	Ziftomenib 400 mg	鹽齋窪糧膚遞觸範構淵(網窪願築壓鑰顧淵積獵) = 衊餘願鹹繭簾齋繭艱繭衊顧窪遞獵製鑰餘鏇鹽 (顧襯範淵襯顧襯願鬱壓 )	-	2024-12-07